Is Pro Medicus Still a Buy at 150x Earnings? What the Valuation Means for Investors

Pro Medicus (ASX: PME) trades at a valuation that defies conventional wisdom. Despite a 25% pullback from July’s $336 peak to around $250, the healthcare imaging software company still commands a price-to-earnings ratio exceeding 260 times trailing earnings. Yet the stock remains up more than 60% over the past year, driven by a record contract pipeline across major US hospital systems. For investors, the critical question isn’t whether the valuation looks expensive on paper; it clearly does. However, the question is whether Pro Medicus’s competitive position can justify what the market is paying.

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

Why Pro Medicus Commands a Premium Valuation

The company’s financial metrics explain the premium. Pro Medicus generates a 51.8% return on equity while carrying zero debt and holding $211 million in cash. This isn’t speculative growth funded by capital raises; it’s a profitable business with proven technology deployed across America’s leading healthcare institutions.
The recurring revenue model generates approximately 90% of sales from long-term contracts that span seven to ten years. What this means for investors is that most of Pro Medicus’s future earnings are already locked in, providing unusual visibility compared to other high-growth technology stocks. Hospitals rarely switch once they adopt Visage 7; the switching costs involve retraining staff, migrating massive medical imaging archives, and disrupting clinical workflows. This creates powerful retention that translates directly into contract renewals and platform expansions.
The cloud-native architecture provides a strategic advantage that competitors struggle to replicate. Unlike legacy vendors forced into hybrid cloud compromises, Pro Medicus built its platform for the cloud from inception, enabling faster deployments and lower infrastructure costs.

The Bull Case: Growth Justifies the Price

Pro Medicus has secured three major US hospital contracts in the first four months of FY26, tripling its pace from the previous year. Recent wins demonstrate the acceleration:

• $170 million, 10-year deal with UCHealth covering 14 hospitals across Colorado, Wyoming, and western Nebraska
• $330 million contract with Trinity Health, one of America’s largest non-profit healthcare systems
• $520 million in total new contracts announced for FY25

For FY25, revenue climbed 31.9% to $213 million, while net profit surged 39.2% to $115.2 million. The key insight here is timing; most contracts signed in the second half of FY25 haven’t yet contributed meaningful revenue. As these implementations roll out through FY26 and beyond, they create a clear revenue pathway supporting continued growth.
The US market represents roughly 60% of global healthcare spending, yet Pro Medicus has penetrated only 8% of this market. The runway remains substantial.

The Bear Case: Risks to Consider

At 200 times forward earnings, the valuation demands near-perfect execution. Any contract delays, implementation setbacks, or broader technology sector rotation could pressure shares significantly. The 25% decline from July’s peak demonstrates how quickly sentiment shifts when expectations sit this high.

Competition poses real threats:

• GE Healthcare, Philips, and Siemens offer competing products backed by broader portfolios, funding research at scale
• Customer concentration creates vulnerability – revenue relies on a relatively small number of large healthcare systems
• Lack of diversification beyond medical imaging exposes the company to regulatory changes affecting healthcare IT spending

These aren’t theoretical concerns. Well-resourced competitors are actively working to close the technology gap Pro Medicus currently enjoys.

The Investor’s Takeaway

Pro Medicus is an exceptional business trading at an extraordinary valuation. The competitive moats are genuine, proven technology, sticky customers, recurring revenue, and cloud advantages that competitors can’t easily replicate. The growth trajectory remains strong, with contracted revenue providing rare visibility for a high-multiple stock.
However, the current 265x earnings multiple prices in years of flawless execution with minimal room for disappointment.

For growth investors comfortable with premium valuations and confident in the US healthcare IT tailwind, the pullback to around $250 offers a better entry than July’s $336 peak, particularly with the RSNA conference approaching as a potential catalyst for fresh contract announcements.

For value-conscious investors, the stock remains expensive even after the 25% decline. Waiting for further consolidation below $240 might provide more comfort. The safest approach may be gradual accumulation during pullbacks rather than lump-sum positions, acknowledging both the business quality and the risk embedded in today’s price.